---
title: "PolyPid falls on wider-than-expected quarterly loss"
date: "2025-02-13 02:32:59"
summary: "** U.S.-listed shares of Israel-based drug developer PolyPid fell 4.7% to $2.75 ** Company, which develops therapies to improve surgical outcomes, posts quarterly loss of $1.13 per share vs analysts' estimate loss of 88 cents** Says independent monitoring board recommended to conclude late-stage study of experimental drug upon enrollment of..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

\*\* U.S.-listed shares of Israel-based drug developer PolyPid fell 4.7% to $2.75

\*\* Company, which develops therapies to improve surgical outcomes, posts quarterly loss of $1.13 per share vs analysts' estimate loss of 88 cents

\*\* Says independent monitoring board recommended to conclude late-stage study of experimental drug upon enrollment of 800 patients

\*\* PYPD is testing the treatment to prevent surgical site infections in patients undergoing a type of abdominal cancer surgery

\*\* Expects to report data from the late-stage in the second quarter of 2025 and plans to submit a marketing application to the FDA if the study meets the main goal

\*\* In the last 12 months, stock has fallen 48.7%

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3P31JZ:0-polypid-falls-on-wider-than-expected-quarterly-loss/)
